Caricamento...
Augmented Interferon-α Pathway Activation in Patients With Sjögren's Syndrome Treated With Etanercept
OBJECTIVE: Recent clinical trials suggest that etanercept is ineffective in controlling Sjögren's syndrome (SS). To address the hypothesis that tumor necrosis factor blockade can result in increased levels of interferon-α (IFNα) and BAFF, we quantified those mediators in plasma from etanercept-...
Salvato in:
| Autori principali: | , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2007
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2737264/ https://ncbi.nlm.nih.gov/pubmed/18050196 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.23062 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|